The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
Brief Report
PreviousPrevious
Volume 351:154-158 July 8, 2004 Number 2
NextNext

Macrolide Resistance in Treponema pallidum in the United States and Ireland
Sheila A. Lukehart, Ph.D., Charmie Godornes, B.S., Barbara J. Molini, M.S., Patricia Sonnett, B.S., Susan Hopkins, M.D., Fiona Mulcahy, M.D., Joseph Engelman, M.D., Samuel J. Mitchell, M.D., Ph.D., Anne M. Rompalo, M.D., Christina M. Marra, M.D., and Jeffrey D. Klausner, M.D., M.P.H.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Supplementary Material

Commentary
-Perspective
 by Hook, E. W.

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
For decades, syphilis infection has been treated with penicillin, and Treponema pallidum has not developed resistance to penicillin. In many countries, the recommended treatment for early syphilis is a single dose of penicillin G benzathine, which maintains bactericidal levels for weeks, killing the slowly metabolizing treponemes. Azithromycin, which has a long tissue half-life and can be administered orally, was found to be effective in the treatment of syphilis in a rabbit model1 and in small studies in humans.2,3,4,5,6 Because of its convenience and efficacy, azithromycin is increasingly being used for the treatment of syphilis by clinicians and in disease-control activities . . . [Full Text of this Article]

Methods

Samples

Gene Sequencing and Restriction-Digestion Analysis

In Vivo Resistance Studies

Results

Clinical Failure of Azithromycin Therapy in a Patient in San Francisco

Identification of the Mutation in the 23S rRNA Genes

Screening of Samples from Multiple Geographic Sites

Confirmation of Azithromycin Resistance in Vivo

Discussion


Source Information

From the Departments of Medicine (S.A.L., C.G., B.J.M., P.S., C.M.M.) and Neurology (C.M.M.), University of Washington, Seattle; St. James Hospital, Dublin (S.H., F.M.); the San Francisco Department of Health, San Francisco (J.E., S.J.M., J.D.K.); the Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta (S.J.M.); and the Department of Medicine, Johns Hopkins University, Baltimore (A.M.R.).

Address reprint requests to Dr. Lukehart at the Department of Medicine, Box 359779, Harborview Medical Center, 325 9th Ave., Seattle, WA 98104, or at lukehart@u.washington.edu.


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.